GI Dynamics’ EndoBarrier Gastrointestinal Liner has demonstrated blood sugar control and weight loss benefits beyond the implant period in the 12-Month Diabetes and Obesity trial.

EndoBarrier is a non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic and obese patients during the implant period.

In the diabetes trial, type II diabetes patients treated with the EndoBarrier for 12 months achieved a mean 2.3% decrease in HbA1c levels, decreased glucose levels from an average of 175.6 at baseline to 137.8 mg/dL and 39% excess weight loss.

It is found that six months after removal of the EndoBarrier, patients experienced only a slight increase in HbA1c levels, from 6.5% to 6.6%.

In the obesity trial, patients reported an average of 46.4% excess weight loss, a mean reduction in HbA1c of 1.4% following 12 months of EndoBarrier treatment.

Six months following the removal of the EndoBarrier, patients maintained as much as 75% of the weight they lost during the treatment period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The EndoBarrier has received CE mark approval in Europe for implant periods of up to 12 months for treating type 2 diabetes and obesity, and recently received TGA approval in Australia.